ArticleHeliyon2024
Lower prevalence of post-Covid-19 Condition following Omicron SARS-CoV-2 infection.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Factors affecting the impact of COVID-19 vaccination on post COVID-19 conditions among adults: A systematic literature review.Human vaccines & immunotherapeutics · 2025Pooled it
- A systematic review and meta-analysis of the impact of vaccination on prevention of long COVID.Nature communications · 2025Pooled it
- Evidence on the associations and safety of COVID-19 vaccination and post COVID-19 condition: an updated living systematic review.Epidemiology and infection · 2025Pooled it
- Observational
- Improving the care of people affected by post-COVID syndrome (LCovB):study protocol of a mixed-methods study.PloS one · 2026Article
- Effects of incentive spirometer training on dyspnea and functional status in patients with long COVID.PloS one · 2026Article
- A perfect storm: the immunological and pathophysiological landscape of pediatric post-COVID-19 condition.Frontiers in immunology · 2026Review
- Post-COVID-19 condition in individuals infected with SARS-CoV-2 in autumn 2023 in the Netherlands: a prospective cohort study with pre- and post-infection data.The Lancet regional health. Europe · 2025Article
- Age-Related Changes in the Clinical Picture of Long COVID.Journal of the American Geriatrics Society · 2025Article
- Article
- Evaluation of the Mutational Preferences Throughout the Whole Genome of the Identified Variants of the SARS-CoV-2 Virus Isolates in Bangladesh.International journal of molecular sciences · 2025Article
- Prospective cohort study of fatigue before and after SARS-CoV-2 infection in the Netherlands.Nature communications · 2025Article
- Article
- Long COVID exhibits clinically distinct phenotypes at 3-6 months post-SARS-CoV-2 infection: results from the P4O2 consortium.BMJ open respiratory research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Different SARS-CoV-2 variants can differentially affect the prevalence of Post Covid-19 Condition (PCC). This prospective study assesses prevalence and severity of symptoms three months after an Omicron infection, compared to Delta, test-negative and population controls. This study also assesses symptomology after reinfection and breakthrough infections. Methods: After a positive SARS-CoV-2 test, cases were classified as Omicron or Delta based on ≥ 85% surveillance prevalence. Three months after enrolment, participants indicated point prevalence for 41 symptoms and severity, using validated questionnaires for four symptoms. PCC prevalence was estimated as the difference in prevalence of at least one significantly elevated symptom, identified by permutation test, in cases compared to population controls. Results: At three months follow-up, five symptoms and severe dyspnea were significantly elevated in Omicron cases (n = 4138) compared to test-negative (n = 1672) and population controls (n = 2762). PCC prevalence was 10·4% for Omicron cases and 17·7% for Delta cases (n = 6855). In Omicron cases, severe fatigue and dyspnea were more prevalent in reinfected than primary infected, while severity of symptoms did not significantly differ between cases with a booster or primary vaccination course. Conclusions: Prevalence of PCC is 41% lower after Omicron than Delta at three months. Reinfection seems associated with more severe long-term symptoms compared to first infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.